Current status of biomarkers in head and neck cancer

Journal of Surgical Oncology

Volumn 97, Issue 8, 2008, Pages 640-643

  Chang, Steven S ^a   Califano, Joseph ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

EGFR; HNSCC; HPV; LOH; Squamous cell carcinoma

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEFITINIB; PLACEBO; TUMOR MARKER; WART VIRUS VACCINE;

ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MECHANISM; GENE LOCUS; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOMATIC MUTATION; VIRUS INFECTION;

BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44949238064     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21023     Document Type: Review

References (53)

1. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Atkinson A, Colburn W, DeGruttola V, et al.: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
3. Koch WM: Clinical implications of biomarkers in head and neck cancer. Curr Oncol Rep 1999;1:129-137.
4. de Bree R, Deurloo EE, Snow GB, et al.: Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000;110:397-401.
5. zur Hausen H: Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-F78.
6. Kreimer AR, Clifford GM, Boyle P, et al.: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475.
7. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-2611.
8. Herrero R, Castellsague X, Pawlita M, et al.: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-1783.
9. Begum S, Gillison ML, Ansari-Lari MA, et al.: Detection of human papillomavirus in cervical lymph nodes: A highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003;9:6469-6475.
10. Koch WM, Bhatti N, Williams MF, et al.: Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 2001;124:331-333.
11. McQuone SJ, Eisele DW, Lee DJ, et al.: Occult tonsillar carcinoma in the unknown primary. Laryngoscope 1998;108:1605-1610.
12. Mendenhall WM, Mancuso AA, Parsons JT, et al.: Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998;20:739-744.
13. Lapeyre M, Malissard L, Peiffert D, et al.: Cervical lymph node metastasis from an unknown primary: Is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys 1997;39:291-296.
14. Mellin H, Friesland S, Lewensohn R, et al.: Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int J Cancer 2000;89:300-304.
15. Lindel K, Beer KT, Laissue J, et al.: Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radio-sensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-813.
16. Weinberger PM, Yu Z, Haffty BG, et al.: Molecular classification identifies a subset of human papillomavirus - associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-747.
17. Li W, Thompson CH, O'Brien CJ, et al.: Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;106:553-558.
18. Schwartz SR, Yueh B, McDougall JK, et al.: Human papillomavirus infection and survival in oral squamous cell cancer: A population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
19. Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
20. Hsu KF, Hung CF, Cheng WF, et al.: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001;8:376-383.
21. Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004;364:1757-1765.
22. Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
23. Capone RB, Pai SI, Koch WM, et al.: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:4171-4175.
24. D'Souza G, Kreimer AR, Viscidi R, et al.: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
25. Maxwell SA, Sacks PG, Gutterman JU, et al.: Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res 1989;49:1130-1137.
26. Kearsley JH, Furlong KL, Cooke RA, et al.: An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Br J Cancer 1990;61:821-827.
27. Ishitoya J, Toriyama M, Oguchi N, et al.: Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br J Cancer 1989;59:559-562.
28. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584.
29. Rubin Grandis J, Melhem MF, Gooding WE, et al.: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832.
30. Chung CH, Ely K, McGavran L, et al.: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-4176.
31. Willmore-Payne C, Holden JA, Layfield LJ: Detection of EGFR-and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19:634-640.
32. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al.: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109-111.
33. Xi S, Zhang Q, Dyer KF, et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278:31574-31583.
34. Zhang Q, Thomas SM, Xi S, et al.: SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-6173.
35. Grandis JR, Drenning SD, Zeng Q, et al.: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97:4227-4232.
36. Bentzen SM, Atasoy BM, Daley FM, et al.: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560-5567.
37. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
38. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 2007;298:70-82.
39. Calvo E, Baselga J: Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24:2158-2163.
40. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-262.
41. Eberhard DA, Johnson BE, Amler LC, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
42. Han SW, Kim TY, Hwang PG, et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501.
43. Mitsudomi T, Kosaka T, Endoh H, et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
44. Taron M, Ichinose Y, Rosell R, et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11:5878-5885.
45. Inoue A, Suzuki T, Fukuhara T, et al.: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346.
46. Asahina H, Yamazaki K, Kinoshita I, et al.: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004.
47. van der Riet P, Nawroz H, Hruban RH, et al.: Frequent loss of chromosome 9p21-22early in head and neck cancer progression. Cancer Res 1994;54:1156-1158.
48. Nawroz H, Koch W, Anker P, et al.: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-1037.
49. Mao L, Lee JS, Fan YH, et al.: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-685.
50. Rosin MP, Cheng X, Poh C, et al.: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-362.
51. Partridge M, Emilion G, Pateromichelakis S, et al.: Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 1998;34:77-83.
52. Tabor MP, Brakenhoff RH, van Houten VM, et al.: Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications. Clin Cancer Res 2001;7:1523-1532.
53. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al.: Genetically altered fields as origin of locally recurrent head and neck cancer: A retrospective study. Clin Cancer Res 2004;10:3607-3613.